Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share
-
Shares outstanding
-
266,212,950
-
Total 13F shares
-
143,479,673
-
Share change
-
-24,720,638
-
Total reported value
-
$233,506,297
-
Put/Call ratio
-
170%
-
Price per share
-
$1.63
-
Number of holders
-
94
-
Value change
-
-$67,552,891
-
Number of buys
-
46
-
Number of sells
-
35
Institutional Holders of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) as of Q3 2025
As of 30 Sep 2025,
Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) was held by
94 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
143,479,673 shares.
The largest 10 holders included
MAK CAPITAL ONE LLC, Blackstone Inc., Syncona Portfolio Ltd, ARMISTICE CAPITAL, LLC, TFG Asset Management GP Ltd, SCHRODER INVESTMENT MANAGEMENT GROUP, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, Frazier Life Sciences Management, L.P., and BlackRock, Inc..
This page lists
94
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.